RSLV-621

N/A

Report date: 2023/12/25 15:01:33

Base Information

Drug NameRSLV-621
Drug Alias NameRSLV-621
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterferon type I inhibitors
TargetsInterferon type I
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesResolve Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesResolve Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A